Table 1. Baseline demographics and clinical characteristics (n=17).
| Variables | Values |
|---|---|
| Age (years) | |
| Mean ± SD | 55.18±11.30 |
| Median (Q1, Q3) | 54.00 (46.00, 63.00) |
| Min, Max | 36, 77 |
| Baseline alpha-fetoprotein level (ng/mL) | |
| Mean ± SD | 3,163.40±9,469.88 |
| Median (Q1, Q3) | 184.00 (21.12, 1,210.00) |
| Min, Max | 1.29, 39,425 |
| White blood cell (109/L) | |
| Mean ± SD | 4.45±2.21 |
| Median (Q1, Q3) | 3.82 (2.96, 4.73) |
| Min, Max | 2.16, 10.39 |
| Red blood cell (1012/L) | |
| Mean ± SD | 3.97±0.53 |
| Median (Q1, Q3) | 3.76 (3.63, 4.38) |
| Min, Max | 3.34, 5.2 |
| Platelets (109/L) | |
| Mean ± SD | 93.65±49.17 |
| Median (Q1, Q3) | 78.00 (56.00, 131.00) |
| Min, Max | 32, 185 |
| Glutamic-pyruvic transaminase (U/L) | |
| Mean ± SD | 38.82±22.98 |
| Median (Q1, Q3) | 32.60 (18.70, 57.90) |
| Min, Max | 11.1, 89.9 |
| Glutamic oxalacetic transaminase (U/L) | |
| Mean ± SD | 47.75±25.63 |
| Median (Q1, Q3) | 38.10 (32.40, 64.40) |
| Min, Max | 17.8, 98.5 |
| Total bilirubin (μmol/L) | |
| Mean ± SD | 16.95±6.96 |
| Median (Q1, Q3) | 16.80 (13.90, 21.40) |
| Min, Max | 4.19, 27.1 |
| Albumin (g/L) | |
| Mean ± SD | 36.54±3.99 |
| Median (Q1, Q3) | 36.10 (33.80, 38.90) |
| Min, Max | 31, 46.7 |
| Des-gamma-carboxyprothrombin (mAU/mL) | |
| Mean ± SD | 3,084.94±6,810.71 |
| Median (Q1, Q3) | 254.00 (35.00, 2,004.00) |
| Min, Max | 16, 27,737 |
| Gender, n (%) | |
| Male | 16 (94.12) |
| Female | 1 (5.88) |
| Eastern Cooperative Oncology Group performance status, n (%) | |
| 0 | 3 (17.65) |
| 1 | 14 (82.35) |
| Aetiology of chronic liver disease, n (%) | |
| Hepatitis B | 14 (82.35) |
| Hepatitis C | 1 (5.88) |
| Unknown | 2 (11.76) |
| Liver function classification, n (%) | |
| 5 | 12 (70.59) |
| 6 | 4 (23.53) |
| 7 | 1 (5.88) |
| Barcelona Clinic Liver Cancer stage, n (%) | |
| B | 9 (52.94) |
| C | 8 (47.06) |
| Vascular invasion, n (%) | |
| No | 16 (94.12) |
| Yes | 1 (5.88) |
| Extrahepatic spread, n (%) | |
| No | 10 (58.82) |
| Yes | 7 (41.18) |
| Metastatic site, n (%) | |
| No | 10 (58.82) |
| Gut | 1 (5.88) |
| Lung | 3 (17.65) |
| Lymph node | 1 (5.88) |
| Adrenal gland | 1 (5.88) |
| Omentum | 1 (5.88) |
| Local treatment, n (%) | |
| Radiotherapy | 2 (11.76) |
| No | 15 (88.24) |
| Previous surgery, n (%) | |
| No | 3 (17.65) |
| Yes | 14 (82.35) |
| Previous TKI†, n (%) | |
| Apatinib | 15 (88.24) |
| Sorafenib | 4 (23.53) |
| Lenvatinib | 2 (11.76) |
| Previous PD-1, n (%) | |
| Camrelizumab | 16 (94.12) |
| Sintilimab | 1 (5.88) |
†, some patients were treated with second-line TKI before switched to regorafenib. SD, standard deviation; Q1, first quartile; Q3, third quartile; TKI, tyrosine kinase inhibitor; PD-1, programmed cell death protein 1.